PharmaNetics (Nasdaq: PHAR), a company specializing in the management of therapeutics affecting coagulation, says that it has completed the target enrollment of 600 patients in its ELECT (EvaLuating Enoxaparin Clotting Times) study.

ELECT is a joint collaboration between Raleigh-based PharmaNetics and cardiologists at The Cleveland Clinic and Duke Clinical Research Institute. Principle investigators David J. Moliterno from Cleveland and James E. Tcheng of Duke coordinated the multi-center study at 17 sites across the United States.

PharmaNetics adds that it expects to announce results at the American Heart Association Meeting in November. ELECT was conducted in patients undergoing angioplasty procedures. The study evaluated the use of PharmaNetics’ lead product, the ENOX test, in facilitating treatment of acute coronary syndrome patients who may transition to angioplasty.

The primary objective of the study is to assess the predictive value of the ENOX test to measure the whole blood anticoagulant effect of the enoxaparin relative to outcomes associated with angioplasty. ENOX is a one-step test, performed on the Rapidpoint Coag analyzer. All of the components necessary to perform the assay, with the exception of the patient sample, are included in the reaction chamber of the test card. The test provides information on the patient’s whole blood response to enoxaparin.

Previous clinical trials have shown enoxaparin to be superior in the treatment of patients with acute coronary syndromes when administered with aspirin, says PharmaNetics. Evolving data also demonstrate that patients who transition to angioplasty earlier in their hospital course have better short-term and intermediate-term outcomes when treated with enoxaparin versus standard heparin.